# Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

> **NCT05519449** · PHASE1 · RECRUITING · sponsor: **Janux Therapeutics** · enrollment: 272 (estimated)

## Conditions studied

- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Castration Resistant Prostatic Cancer

## Interventions

- **BIOLOGICAL:** JANX007
- **DRUG:** Darolutamide

## Key facts

- **NCT ID:** NCT05519449
- **Lead sponsor:** Janux Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-15
- **Primary completion:** 2027-07
- **Final completion:** 2028-12
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05519449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05519449, "Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05519449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*